Sector Alpha Week of 2026-08-04
20-quarter listed-company comparison

Medical Instruments & Supplies Stocks

Medical Instruments & Supplies: Medline Inc. owns the largest revenue base; MiniMed Group, Inc. has the fastest current growth.

01 · the industry itself · before any single company

How has Medical Instruments & Supplies moved against S&P 500?

The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the most recent two of them this industry is 30% behind S&P 500. Earnings across its companies grew 4% on average over the last four reported quarters — close to flat. It has been ahead of S&P 500 on a rolling three-month view for 7 weeks running.

BREAKING OUT · ahead 7w✓Price down, no fundamental support23 of 36 companies ahead of S&P 500 by 5% or more over three months3 are 20% or more behind over a year while earnings grew 20% or more

RS ↑7w · 29/36 >200d (+4) · 23/36 lead (+6) · EPS 24/35↑

20020262025202420232022 204348 TRAILING 12-MONTH EPS · 100 AT THE START0100Mar 22Sep 22Mar 23Sep 23Mar 24Sep 24Mar 25Sep 25Mar 26Mar 2022 · trailing 12-month earnings per share at 100, against 100 at the start · no comparable year yet · 22 reportingJun 2022 · trailing 12-month earnings per share at 100, against 100 at the start · no comparable year yet · 25 reportingSep 2022 · trailing 12-month earnings per share at 92, against 100 at the start · no comparable year yet · 27 reportingDec 2022 · trailing 12-month earnings per share at 81, against 100 at the start · no comparable year yet · 25 reportingMar 2023 · trailing 12-month earnings per share at 78, against 100 at the start · down 19.1% on a year ago · 24 reportingJun 2023 · trailing 12-month earnings per share at 76, against 100 at the start · down 23.9% on a year ago · 25 reportingSep 2023 · trailing 12-month earnings per share at 76, against 100 at the start · down 21.7% on a year ago · 25 reportingDec 2023 · trailing 12-month earnings per share at 74, against 100 at the start · down 2.0% on a year ago · 27 reportingMar 2024 · trailing 12-month earnings per share at 68, against 100 at the start · down 11.0% on a year ago · 26 reportingJun 2024 · trailing 12-month earnings per share at 70, against 100 at the start · down 3.1% on a year ago · 26 reportingSep 2024 · trailing 12-month earnings per share at 60, against 100 at the start · up 6.8% on a year ago · 26 reportingDec 2024 · trailing 12-month earnings per share at 52, against 100 at the start · up 0.5% on a year ago · 26 reportingMar 2025 · trailing 12-month earnings per share at 53, against 100 at the start · down 7.8% on a year ago · 26 reportingJun 2025 · trailing 12-month earnings per share at 55, against 100 at the start · up 0.7% on a year ago · 26 reportingSep 2025 · trailing 12-month earnings per share at 50, against 100 at the start · down 0.3% on a year ago · 26 reportingDec 2025 · trailing 12-month earnings per share at 64, against 100 at the start · up 5.4% on a year ago · 25 reportingMar 2026 · trailing 12-month earnings per share at 67, against 100 at the start · up 8.5% on a year ago · 25 reportingNot reported yet — earnings trail price by a quarter or two67 · Mar 26No earnings on file this far back — the price series reaches further than the filings do
20020262025202420232022 204348 TRAILING 12-MONTH EPS · 100 AT THE START0100Mar 22Mar 23Mar 24Mar 25Mar 26Mar 2022 · trailing 12-month earnings per share at 100, against 100 at the start · no comparable year yet · 22 reportingJun 2022 · trailing 12-month earnings per share at 100, against 100 at the start · no comparable year yet · 25 reportingSep 2022 · trailing 12-month earnings per share at 92, against 100 at the start · no comparable year yet · 27 reportingDec 2022 · trailing 12-month earnings per share at 81, against 100 at the start · no comparable year yet · 25 reportingMar 2023 · trailing 12-month earnings per share at 78, against 100 at the start · down 19.1% on a year ago · 24 reportingJun 2023 · trailing 12-month earnings per share at 76, against 100 at the start · down 23.9% on a year ago · 25 reportingSep 2023 · trailing 12-month earnings per share at 76, against 100 at the start · down 21.7% on a year ago · 25 reportingDec 2023 · trailing 12-month earnings per share at 74, against 100 at the start · down 2.0% on a year ago · 27 reportingMar 2024 · trailing 12-month earnings per share at 68, against 100 at the start · down 11.0% on a year ago · 26 reportingJun 2024 · trailing 12-month earnings per share at 70, against 100 at the start · down 3.1% on a year ago · 26 reportingSep 2024 · trailing 12-month earnings per share at 60, against 100 at the start · up 6.8% on a year ago · 26 reportingDec 2024 · trailing 12-month earnings per share at 52, against 100 at the start · up 0.5% on a year ago · 26 reportingMar 2025 · trailing 12-month earnings per share at 53, against 100 at the start · down 7.8% on a year ago · 26 reportingJun 2025 · trailing 12-month earnings per share at 55, against 100 at the start · up 0.7% on a year ago · 26 reportingSep 2025 · trailing 12-month earnings per share at 50, against 100 at the start · down 0.3% on a year ago · 26 reportingDec 2025 · trailing 12-month earnings per share at 64, against 100 at the start · up 5.4% on a year ago · 25 reportingMar 2026 · trailing 12-month earnings per share at 67, against 100 at the start · up 8.5% on a year ago · 25 reportingNot reported yet — earnings trail price by a quarter or two67No earnings on file this far back — the price series reaches further than the filings do
Medical Instruments & Supplies, equal-weighted, based at 200 S&P 500, same base, same start trailing 12-month earnings per share rising falling

Both lines start at 200 in the same week, so the distance between them is the whole story: the industry line is an equal-weighted index of its 36 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the industry taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.

02 · sector relative strength, before individual stocks

Is Medical Instruments & Supplies outperforming S&P 500?

Medical Instruments & Supplies has outperformed S&P 500 by 2.3% over the last 52 weeks. Over 13 weeks the gap is a lead of 18.1%. 13 of 27 covered companies currently beat the S&P 500 on Mansfield relative strength, so leadership inside the sector is selective. Pulse Biosciences, Inc. is the strongest against the sector itself at +62.3%.

+18.1%Sector vs S&P 500 · 13 weeks
+2.3%Sector vs S&P 500 · 52 weeks
13/27Stocks leading S&P 500
10/27Stocks leading sector

Sector metric: — as of latest available · unclassified · direction unavailable.

The central tension: the companies with the most scale are not necessarily the companies creating the most change.

Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.

Bottom line

Medical Instruments & Supplies has outperformed S&P 500 by 2.3% over 52 weeks and 18.1% over 13 weeks. 13 of 27 covered companies beat the S&P 500 on Mansfield relative strength, while 10 of 27 beat the sector itself. Medline Inc. leads with revenue of $29,140 million, based on 14 of 30 comparable companies through Mar 2026.

Companies
30
complete canonical membership
Combined market value
$464.6B
Intuitive Surgical, Inc.
Revenue growing
10/14
positive TTM year-on-year growth
Beating S&P 500
13/27
positive Mansfield relative strength
Comparing 5 of 30
03 · research priority, made explicit

4-Factor Sector Score

An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.

Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%
LeMaitre Vascular, Inc. has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 81.1% evidence confidence.
Avantor, Inc. has stronger price confirmation than earnings confirmation; that is a research prompt, not permission to chase.
How this score is built, and what the marks mean

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1LeMaitre Vascular, Inc.LMAT 61.8/100Mixed-positive evidence81% evidence BASING 26.4/35 Revenue 12.8% · PAT 40% · OPM change 5.6 pp 83% evidence 16.2/25 ROCE 3.2% · OPM 26.7% 76% evidence 13.8/20 P/E 40.3× · PEG 1.09 65% evidence 5.4/20 RS sector -5.2% · RS bench -0.3% · 1Y 14.6%0 of 12 weeks ahead 100% evidence
Exact sum: 26.4 + 16.2 + 13.8 + 5.4 = 61.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -5.2% and the one-year return is 14.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
2West Pharmaceutical Services, Inc.WST 60.6/100Thin evidence · provisional58% evidence FADING 21.5/35 Revenue — · PAT — · OPM change 5.7 pp 45% evidence 17.1/25 ROCE 5.3% · OPM 21% 76% evidence 9.6/20 P/E 46× · PEG — 15% evidence 12.4/20 RS sector 6.1% · RS bench 11.8% · 1Y 44.7%10 of 12 weeks ahead 100% evidence
Exact sum: 21.5 + 17.1 + 9.6 + 12.4 = 60.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
3Baxter International Inc.BAX 57.3/100Thin evidence · provisional58% evidence BREAKING OUT 17.6/35 Revenue — · PAT — · OPM change 0.2 pp 45% evidence 10.0/25 ROCE 1.3% · OPM 2.4% 76% evidence 10.2/20 P/E 39.6× · PEG — 15% evidence 19.5/20 RS sector 18.6% · RS bench 24.1% · 1Y 19.7%9 of 12 weeks ahead 100% evidence
Exact sum: 17.6 + 10 + 10.2 + 19.5 = 57.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
4Avantor, Inc.AVTR 56.6/100Thin evidence · provisional58% evidence BREAKING OUT 15.4/35 Revenue — · PAT — · OPM change -3 pp 45% evidence 11.3/25 ROCE 1.2% · OPM 6.3% 76% evidence 11.3/20 P/E 13.6× · PEG — 15% evidence 18.6/20 RS sector 8.9% · RS bench 13.4% · 1Y 19%9 of 12 weeks ahead 100% evidence
Exact sum: 15.4 + 11.3 + 11.3 + 18.6 = 56.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
5ResMed Inc.RMD 55.5/100Mixed-positive evidence81% evidence TURNING 22.6/35 Revenue 10.3% · PAT 15.8% · OPM change 1.9 pp 83% evidence 17.6/25 ROCE 7.1% · OPM 34.9% 76% evidence 13.5/20 P/E 21.6× · PEG 1.32 65% evidence 1.8/20 RS sector -20.3% · RS bench -16.8% · 1Y -21.4%0 of 12 weeks ahead 100% evidence
Exact sum: 22.6 + 17.6 + 13.5 + 1.8 = 55.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6Merit Medical Systems, Inc.MMSI 54.3/100Thin evidence · provisional58% evidence TURNING 18.8/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence 14.8/25 ROCE 2.4% · OPM 11.6% 76% evidence 10.5/20 P/E 28.7× · PEG — 15% evidence 10.2/20 RS sector -5.8% · RS bench -1.6% · 1Y 0.3%2 of 12 weeks ahead 100% evidence
Exact sum: 18.8 + 14.8 + 10.5 + 10.2 = 54.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
7Solventum CorporationSOLV 50.9/100Mixed-positive evidence71% evidence BREAKING OUT 16.7/35 Revenue -0.6% · PAT 100% · OPM change -3.3 pp 83% evidence 11.3/25 ROCE 0.7% · OPM 4% 76% evidence 11.4/20 P/E 8× · PEG — 15% evidence 11.5/20 RS sector 0% · RS bench 4.9% · 1Y 19.8%9 of 12 weeks ahead 100% evidence
Exact sum: 16.7 + 11.3 + 11.4 + 11.5 = 50.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8Envista Holdings CorporationNVST 50.7/100Thin evidence · provisional58% evidence TURNING 19.0/35 Revenue — · PAT — · OPM change 2.1 pp 45% evidence 11.4/25 ROCE 1.2% · OPM 8.9% 76% evidence 9.3/20 P/E 63× · PEG — 15% evidence 11.0/20 RS sector 0.4% · RS bench 5.6% · 1Y 38.1%1 of 12 weeks ahead 100% evidence
Exact sum: 19 + 11.4 + 9.3 + 11 = 50.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
9AtriCure, Inc.ATRC 50.6/100Thin evidence · provisional52% evidence BREAKING OUT 21.4/35 Revenue — · PAT — · OPM change 5.2 pp 45% evidence 9.1/25 ROCE 1.7% · OPM 0.4% 76% evidence 9.0/20 P/E 133.2× · PEG — 15% evidence 11.1/20 RS sector -1.4% · RS bench 2.9% · 1Y 10.5%5 of 12 weeks ahead 70% evidence
Exact sum: 21.4 + 9.1 + 9 + 11.1 = 50.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
10Intuitive Surgical, Inc.ISRG 49.2/100Thin evidence · provisional58% evidence ASLEEP 22.1/35 Revenue — · PAT — · OPM change 5.2 pp 45% evidence 17.0/25 ROCE 5.2% · OPM 30.9% 76% evidence 9.7/20 P/E 45.6× · PEG — 15% evidence 0.4/20 RS sector -33.7% · RS bench -30.6% · 1Y -21.7%0 of 12 weeks ahead 100% evidence
Exact sum: 22.1 + 17 + 9.7 + 0.4 = 49.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
11STAAR Surgical CompanySTAA 49.0/100Thin evidence · provisional52% evidence ASLEEP 23.7/35 Revenue — · PAT — · OPM change 76.1 pp 45% evidence 12.0/25 ROCE 2% · OPM 8.5% 76% evidence 9.1/20 P/E 84.6× · PEG — 15% evidence 4.2/20 RS sector -17.3% · RS bench -12.9% · 1Y -11.5%7 of 12 weeks ahead 70% evidence
Exact sum: 23.7 + 12 + 9.1 + 4.2 = 49 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
12ICU Medical, Inc.ICUI 48.7/100Mixed-negative evidence64% evidence BREAKING OUT 14.1/35 Revenue -10.9% · PAT — · OPM change 0.5 pp 62% evidence 7.8/25 ROCE 0.4% · OPM 2.6% 76% evidence 9.2/20 P/E 69.8× · PEG — 15% evidence 17.6/20 RS sector 6.9% · RS bench 12.1% · 1Y 52.4%6 of 12 weeks ahead 100% evidence
Exact sum: 14.1 + 7.8 + 9.2 + 17.6 = 48.7 · Decision use: Price leads the evidence: RS versus the benchmark is 12.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
13Align Technology, Inc.ALGN 47.9/100Thin evidence · provisional58% evidence ASLEEP 17.0/35 Revenue — · PAT — · OPM change 0.2 pp 45% evidence 15.8/25 ROCE 3.5% · OPM 13.6% 76% evidence 10.4/20 P/E 29.3× · PEG — 15% evidence 4.7/20 RS sector -8.4% · RS bench -3.6% · 1Y 23.9%0 of 12 weeks ahead 100% evidence
Exact sum: 17 + 15.8 + 10.4 + 4.7 = 47.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
14AptarGroup, Inc.ATR 47.3/100Thin evidence · provisional58% evidence TURNING 14.8/35 Revenue — · PAT — · OPM change -1.9 pp 45% evidence 15.2/25 ROCE 3.4% · OPM 10.9% 76% evidence 10.9/20 P/E 22.6× · PEG — 15% evidence 6.4/20 RS sector -8.6% · RS bench -4.2% · 1Y -3.2%2 of 12 weeks ahead 100% evidence
Exact sum: 14.8 + 15.2 + 10.9 + 6.4 = 47.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
15Warby Parker Inc.WRBY 45.8/100Thin evidence · provisional58% evidence FADING 15.9/35 Revenue 11.9% · PAT — · OPM change -0.4 pp 62% evidence 6.8/25 ROCE 0.3% · OPM 0.7% 76% evidence 8.5/20 P/E 1053.5× · PEG — 15% evidence 14.6/20 RS sector 4.2% · RS bench 9.4% · 1Y 28.2%4 of 12 weeks ahead 70% evidence
Exact sum: 15.9 + 6.8 + 8.5 + 14.6 = 45.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
16Medline Inc.MDLN 45.6/100Thin evidence · provisional51% evidence TURNING 13.1/35 Revenue 12.1% · PAT -12.5% · OPM change -2.9 pp 83% evidence 12.2/25 ROCE 1.2% · OPM 5.7% 76% evidence 10.3/20 P/E 32.6× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y —0 of 12 weeks ahead 0% evidence
Exact sum: 13.1 + 12.2 + 10.3 + 10 = 45.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
17Repligen CorporationRGEN 45.1/100Thin evidence · provisional58% evidence BREAKING OUT 18.8/35 Revenue — · PAT — · OPM change 4.3 pp 45% evidence 10.3/25 ROCE 0.5% · OPM 8.2% 76% evidence 8.9/20 P/E 186.9× · PEG — 15% evidence 7.1/20 RS sector -6.8% · RS bench -2.5% · 1Y 34.4%7 of 12 weeks ahead 100% evidence
Exact sum: 18.8 + 10.3 + 8.9 + 7.1 = 45.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
18Stevanato Group S.p.A.STVN 44.4/100Mixed-negative evidence81% evidence FADING 19.0/35 Revenue 6.9% · PAT 12.7% · OPM change 0.7 pp 83% evidence 14.8/25 ROCE 2% · OPM 14.2% 76% evidence 7.1/20 P/E 23.3× · PEG 2.74 65% evidence 3.5/20 RS sector -14.8% · RS bench -10.9% · 1Y -16.8%9 of 12 weeks ahead 100% evidence
Exact sum: 19 + 14.8 + 7.1 + 3.5 = 44.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
19Bausch + Lomb CorporationBLCO 41.0/100Thin evidence · provisional58% evidence ASLEEP 20.9/35 Revenue — · PAT — · OPM change 10 pp 45% evidence 8.5/25 ROCE 0.7% · OPM 2.7% 76% evidence 8.6/20 P/E 775.5× · PEG — 15% evidence 3.0/20 RS sector -11.2% · RS bench -6.8% · 1Y 22.3%0 of 12 weeks ahead 100% evidence
Exact sum: 20.9 + 8.5 + 8.6 + 3 = 41 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
20DENTSPLY SIRONA Inc.XRAY 40.6/100Mixed-negative evidence64% evidence TURNING 8.9/35 Revenue -1% · PAT — · OPM change -11.2 pp 62% evidence 5.5/25 ROCE -0.8% · OPM -4% 76% evidence 11.0/20 P/E 22.6× · PEG — 15% evidence 15.2/20 RS sector 0.5% · RS bench 5.1% · 1Y 10.1%4 of 12 weeks ahead 100% evidence
Exact sum: 8.9 + 5.5 + 11 + 15.2 = 40.6 · Decision use: Price leads the evidence: RS versus the benchmark is 5.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
21Teleflex IncorporatedTFX 34.3/100Adverse evidence71% evidence TURNING 6.4/35 Revenue -32.4% · PAT -138.7% · OPM change -14.6 pp 83% evidence 8.9/25 ROCE 0.3% · OPM 3.7% 76% evidence 10.7/20 P/E 28× · PEG — 15% evidence 8.3/20 RS sector -2.1% · RS bench 2.8% · 1Y 18.3%4 of 12 weeks ahead 100% evidence
Exact sum: 6.4 + 8.9 + 10.7 + 8.3 = 34.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
22Becton, Dickinson and CompanyBDX 33.9/100Adverse evidence81% evidence TURNING 12.7/35 Revenue 6.4% · PAT 4.8% · OPM change -6.5 pp 83% evidence 8.8/25 ROCE 0.2% · OPM 2% 76% evidence 8.7/20 P/E 39.8× · PEG 2.42 65% evidence 3.7/20 RS sector -17.1% · RS bench -13.4% · 1Y -12.1%2 of 12 weeks ahead 100% evidence
Exact sum: 12.7 + 8.8 + 8.7 + 3.7 = 33.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
23Azenta, Inc.AZTA 30.1/100Thin evidence · provisional58% evidence BREAKING OUT 8.4/35 Revenue 2% · PAT — · OPM change -101.8 pp 62% evidence 4.4/25 ROCE -9.6% · OPM -114.5% 76% evidence 11.5/20 P/E 2.1× · PEG — 15% evidence 5.8/20 RS sector -9.3% · RS bench -5.5% · 1Y 3.8%3 of 12 weeks ahead 70% evidence
Exact sum: 8.4 + 4.4 + 11.5 + 5.8 = 30.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
24Alcon Inc.ALC 29.7/100Adverse evidence81% evidence TURNING 10.7/35 Revenue 7.1% · PAT -26.9% · OPM change -8.1 pp 83% evidence 9.9/25 ROCE 0% · OPM 10.8% 76% evidence 4.8/20 P/E 45.4× · PEG 6.35 65% evidence 4.3/20 RS sector -19.5% · RS bench -15.7% · 1Y -17.2%1 of 12 weeks ahead 100% evidence
Exact sum: 10.7 + 9.9 + 4.8 + 4.3 = 29.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
25The Cooper Companies, Inc.COO 28.6/100Adverse evidence85% evidence TURNING 7.2/35 Revenue 6.1% · PAT -43.1% · OPM change -21.3 pp 95% evidence 7.8/25 ROCE -0.3% · OPM -2.9% 76% evidence 6.9/20 P/E 53.3× · PEG 2.6 65% evidence 6.7/20 RS sector -12.1% · RS bench -8% · 1Y 6.3%3 of 12 weeks ahead 100% evidence
Exact sum: 7.2 + 7.8 + 6.9 + 6.7 = 28.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
26Pulse Biosciences, Inc.PLSE 54.3/100Thin evidence · provisional42% evidence BREAKING OUT 19.3/35 Revenue — · PAT — · OPM change 98992.5 pp 19% evidence 5.0/25 ROCE -19.4% · OPM — 61% evidence 10.0/20 P/E — · PEG — 0% evidence 20.0/20 RS sector 62.3% · RS bench 71.4% · 1Y 159.5%10 of 12 weeks ahead 100% evidence
Exact sum: 19.3 + 5 + 10 + 20 = 54.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
27BioLife Solutions, Inc.BLFS 48.8/100Thin evidence · provisional47% evidence BREAKING OUT 17.8/35 Revenue — · PAT — · OPM change 2.4 pp 32% evidence 6.0/25 ROCE 0% · OPM 0.1% 76% evidence 8.7/20 P/E 228.4× · PEG — 15% evidence 16.3/20 RS sector 12.8% · RS bench 18.1% · 1Y 43.4%10 of 12 weeks ahead 70% evidence
Exact sum: 17.8 + 6 + 8.7 + 16.3 = 48.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
28MiniMed Group, Inc.MMED 48.5/100Thin evidence · provisional44% evidence TURNING 24.1/35 Revenue 14.3% · PAT — · OPM change 9.3 pp 71% evidence 4.4/25 ROCE -2.5% · OPM -11.1% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 10.0/20 RS sector — · RS bench — · 1Y —4 of 9 weeks ahead 0% evidence
Exact sum: 24.1 + 4.4 + 10 + 10 = 48.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
29Alamar Biosciences, Inc.ALMR 41.2/100Thin evidence · provisional24% evidence TURNING 17.7/35 Revenue — · PAT — · OPM change 17.9 pp 13% evidence 3.5/25 ROCE -15.2% · OPM -47.4% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 10.0/20 RS sector — · RS bench — · 1Y —1 of 3 weeks ahead 0% evidence
Exact sum: 17.7 + 3.5 + 10 + 10 = 41.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
30Kestra Medical Technologies, Ltd.KMTS 41.0/100Thin evidence · provisional49% evidence TURNING 18.0/35 Revenue — · PAT — · OPM change -5.1 pp 45% evidence 3.6/25 ROCE -13.9% · OPM -141.6% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 9.4/20 RS sector -3.6% · RS bench 1% · 1Y 78.6%4 of 12 weeks ahead 70% evidence
Exact sum: 18 + 3.6 + 10 + 9.4 = 41 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
Showing 10 of 30 companies
04 · what price has already done

Market action

Pulse Biosciences, Inc. has the strongest one-year price move in Medical Instruments & Supplies at +159.5%. It also leads on Mansfield relative strength against the S&P 500 at +71.4%. 13 of 27 covered companies are above zero on that measure. Every line covers 314 weekly closes through 2026-08-04.

Price and relative strength

Every company, the sector's own index and S&P 500 all start level on the left edge of the window, so only the distance between the lines counts — the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.

05 · compare level, then change

Revenue Scale & Growth Durability

Medline Inc. has the highest Revenue among the 30 Medical Instruments & Supplies companies compared here, at $29,140 million. Becton, Dickinson and Company is next at $21,366 million. MiniMed Group, Inc. has the highest Revenue growth at 14.3%, so level and change sit with different companies. 14 of 30 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: Medline Inc. is the scale leader at $29,140 million, 36.4% ahead of Becton, Dickinson and Company. MiniMed Group, Inc.'s growth is 14.3% from a $3,103 million base, with 8 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.

LeaderMedline Inc. · $29,140 million
Gap36.4% versus #2 · Becton, Dickinson and Company
Persistence5/5 recent comparable periods
Coverage14/30 companies · 506 observations

Investor read: Medline Inc. is the scale benchmark; MiniMed Group, Inc. is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.

This conclusion weakens if: Medline Inc.'s growth falls below MiniMed Group, Inc.'s for two consecutive comparable reports while operating margin also compresses.

Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
1Medline Inc. MDLN$29.1B
2Becton, Dickinson and Company BDX$21.4B
3Alcon Inc. ALC$10.6B
4Solventum Corporation SOLV$8.3B
5ResMed Inc. RMD$5.5B
Revenue growthfastest growers
1MiniMed Group, Inc. MMED14%
2LeMaitre Vascular, Inc. LMAT13%
3Medline Inc. MDLN12%
4Warby Parker Inc. WRBY12%
5ResMed Inc. RMD10%
Revenue · company comparison
14/30 level · 14/30 change

On every company-comparison chart on this page: solid lines show level, dotted lines show change when “Both” is selected, and a missing report breaks the line rather than being invented.

All-company data · latest reported quarter

In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

CompanyRevenueRevenue growthReported
Medline Inc. MDLN$7.4B11%Mar 2026
Becton, Dickinson and Company BDX$4.7B5.2%Mar 2026
Intuitive Surgical, Inc. ISRG$2.8B23%Jun 2026
Alcon Inc. ALC$2.7B9.4%Mar 2026
Baxter International Inc. BAX$2.7B2.9%Jun 2026
Solventum Corporation SOLV$2.0B-3.0%Mar 2026
Avantor, Inc. AVTR$1.6B0.0%Jun 2026
ResMed Inc. RMD$1.4B11%Mar 2026
Bausch + Lomb Corporation BLCO$1.2B9.4%Jun 2026
The Cooper Companies, Inc. COO$1.1B8.0%Jun 2026
Align Technology, Inc. ALGN$1.0B6.2%Jun 2026
AptarGroup, Inc. ATR$983M11%Jun 2026
DENTSPLY SIRONA Inc. XRAY$880M0.1%Mar 2026
West Pharmaceutical Services, Inc. WST$845M21%Jun 2026
MiniMed Group, Inc. MMED$837M16%Jun 2026
Envista Holdings Corporation NVST$706M3.5%Jun 2026
Teleflex Incorporated TFX$548M32%Mar 2026
ICU Medical, Inc. ICUI$530M-12%Mar 2026
Merit Medical Systems, Inc. MMSI$382M7.6%Jun 2026
Stevanato Group S.p.A. STVN$274M6.6%Mar 2026
Warby Parker Inc. WRBY$242M8.0%Mar 2026
Repligen Corporation RGEN$194M15%Jun 2026
Azenta, Inc. AZTA$145M1.4%Mar 2026
AtriCure, Inc. ATRC$141M14%Jun 2026
STAAR Surgical Company STAA$94M114%Jun 2026
LeMaitre Vascular, Inc. LMAT$67M12%Mar 2026
BioLife Solutions, Inc. BLFS$28M27%Mar 2026
Alamar Biosciences, Inc. ALMR$26M100%Mar 2026
Kestra Medical Technologies, Ltd. KMTS$25M67%Jun 2026
Pulse Biosciences, Inc. PLSE$0M-100%Mar 2026
Full 20-quarter history · every available company

Revenue · reported quarter history

Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alcon Inc. · ALC

$2.1B
$2.1B
$2.2B
$2.2B
$2.1B
$2.2B
$2.4B
$2.4B
$2.3B
$2.4B
$2.5B
$2.5B
$2.5B
$2.5B
$2.5B
$2.6B
$2.6B
$2.7B
$2.7B
—

Align Technology, Inc. · ALGN

$1.0B
$1.0B
$973M
$970M
$890M
$902M
$943M
$1.0B
$960M
$957M
$997M
$1.0B
$978M
$995M
$979M
$1.0B
$996M
$1.0B
$1.0B
—

AptarGroup, Inc. · ATR

$825M
$814M
$845M
$845M
$837M
$796M
$860M
$896M
$893M
$838M
$915M
$910M
$909M
$848M
$887M
$966M
$961M
$963M
$983M
—

Avantor, Inc. · AVTR

$1.8B
$1.9B
$2.0B
$1.9B
$1.9B
$1.8B
$1.8B
$1.7B
$1.7B
$1.7B
$1.7B
$1.7B
$1.7B
$1.7B
$1.6B
$1.7B
$1.6B
$1.7B
$1.6B
—

Baxter International Inc. · BAX

$3.2B
$3.5B
$3.7B
$3.6B
$3.6B
$3.7B
$3.5B
$3.7B
$2.6B
$2.7B
$2.5B
$2.7B
$2.7B
$2.8B
$2.6B
$2.8B
$2.8B
$3.0B
$2.7B
—

Becton, Dickinson and Company · BDX

$4.8B
$4.7B
$4.8B
$4.6B
$4.8B
$4.6B
$4.8B
$4.9B
$5.1B
$4.7B
$5.0B
$5.0B
$5.4B
$5.2B
$4.5B
$5.5B
$5.9B
$5.3B
$4.7B
—

Intuitive Surgical, Inc. · ISRG

$1.4B
$1.6B
$1.5B
$1.5B
$1.6B
$1.7B
$1.7B
$1.8B
$1.7B
$1.9B
$1.9B
$2.0B
$2.0B
$2.4B
$2.3B
$2.4B
$2.5B
$2.9B
$2.8B
—

Medline Inc. · MDLN

—
—
—
—
—
—
—
—
—
—
$6.2B
$6.2B
$6.4B
$6.8B
$6.6B
$6.9B
$7.1B
$7.8B
$7.4B
—

ResMed Inc. · RMD

$904M
$895M
$865M
$915M
$950M
$1.0B
$1.1B
$1.1B
$1.1B
$1.2B
$1.2B
$1.2B
$1.2B
$1.3B
$1.3B
$1.3B
$1.3B
$1.4B
$1.4B
—

Solventum Corporation · SOLV

—
—
$2.1B
$2.1B
$2.0B
$2.0B
$2.0B
$2.1B
$2.1B
$2.0B
$2.0B
$2.1B
$2.1B
$2.1B
$2.1B
$2.2B
$2.1B
$2.0B
$2.0B
—

The Cooper Companies, Inc. · COO

$763M
$759M
$787M
$830M
$843M
$848M
$859M
$877M
$930M
$927M
$932M
$943M
$1.0B
$1.0B
$965M
$1.0B
$1.1B
$1.1B
$1.0B
$1.1B

West Pharmaceutical Services, Inc. · WST

$707M
$731M
$720M
$771M
$687M
$709M
$717M
$754M
$747M
$732M
$695M
$702M
$747M
$749M
$698M
$767M
$805M
$805M
$845M
—

Revenue growth · reported quarter history

Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alcon Inc. · ALC

—
—
—
5.1%
1.8%
1.0%
7.5%
9.3%
8.8%
8.3%
4.6%
3.1%
5.4%
6.4%
0.6%
4.0%
6.5%
8.6%
9.4%
—

Align Technology, Inc. · ALGN

—
—
—
-4.1%
-12%
-13%
-3.1%
3.3%
7.9%
6.1%
5.7%
2.6%
1.9%
4.0%
-1.8%
-1.6%
1.8%
5.3%
6.2%
—

AptarGroup, Inc. · ATR

—
—
—
4.2%
1.5%
-2.2%
1.8%
6.0%
6.7%
5.3%
6.4%
1.6%
1.8%
1.2%
-3.1%
6.2%
5.7%
14%
11%
—

Avantor, Inc. · AVTR

—
—
—
2.8%
1.3%
-5.9%
-8.7%
-8.7%
-7.4%
-4.0%
-5.6%
-2.4%
-0.4%
-2.1%
-5.9%
-1.2%
-5.3%
-1.4%
0.0%
—

Baxter International Inc. · BAX

—
—
—
16%
12%
6.6%
-5.2%
3.1%
-28%
-27%
-29%
-27%
3.9%
1.0%
5.4%
4.3%
5.0%
8.0%
2.9%
—

Becton, Dickinson and Company · BDX

—
—
—
0.7%
-1.8%
-2.8%
1.5%
5.1%
6.9%
2.6%
4.7%
2.3%
6.9%
9.8%
-11%
10%
8.4%
1.6%
5.2%
—

Intuitive Surgical, Inc. · ISRG

—
—
—
4.0%
11%
6.7%
14%
15%
12%
17%
12%
14%
17%
25%
19%
21%
23%
19%
23%
—

Medline Inc. · MDLN

—
—
—
—
—
—
—
—
—
—
—
—
—
—
8.0%
11%
11%
15%
11%
—

ResMed Inc. · RMD

—
—
—
4.5%
5.1%
16%
29%
23%
16%
12%
7.2%
9.0%
11%
10%
7.9%
10%
9.1%
11%
11%
—

Solventum Corporation · SOLV

—
—
—
—
—
—
-2.3%
0.9%
3.2%
1.6%
0.3%
0.2%
0.4%
1.9%
2.7%
3.8%
0.7%
-3.7%
-3.0%
—

The Cooper Companies, Inc. · COO

—
—
—
—
10%
12%
9.2%
5.7%
10%
9.3%
8.5%
7.5%
7.9%
9.8%
3.5%
6.3%
5.7%
4.6%
6.1%
8.0%

West Pharmaceutical Services, Inc. · WST

—
—
—
6.5%
-2.8%
-3.0%
-0.4%
-2.2%
8.7%
3.2%
-3.1%
-6.9%
0.0%
2.3%
0.4%
9.3%
7.8%
7.5%
21%
—
06 · compare level, then change

Operating Economics & Margin Trend

ResMed Inc. has the highest OPM among the 30 Medical Instruments & Supplies companies compared here, at 34.9%. Intuitive Surgical, Inc. is next at 30.9%. Pulse Biosciences, Inc. has the highest Margin change at +98992.5 percentage points, so level and change sit with different companies. 29 of 30 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: ResMed Inc. leads opm at 34.9%; Pulse Biosciences, Inc. leads margin change at +98992.5 percentage points.

LeaderResMed Inc. · 34.9%
Gap12.9% versus #2 · Intuitive Surgical, Inc.
Persistence8/8 recent comparable periods
Coverage29/30 companies · 498 observations

Investor read: ResMed Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
1ResMed Inc. RMD35%
2Intuitive Surgical, Inc. ISRG31%
3LeMaitre Vascular, Inc. LMAT27%
4West Pharmaceutical Services, Inc. WST21%
5Stevanato Group S.p.A. STVN14%
Margin changefastest expanders
1Pulse Biosciences, Inc. PLSE+98,992.5 pp
2STAAR Surgical Company STAA+76.1 pp
3Alamar Biosciences, Inc. ALMR+17.9 pp
4Bausch + Lomb Corporation BLCO+10.0 pp
5MiniMed Group, Inc. MMED+9.3 pp
Operating margin · company comparison
29/30 level · 30/30 change
All-company data · latest reported quarter
CompanyOPMMargin changeReported
ResMed Inc. RMD35%+1.9 ppMar 2026
Intuitive Surgical, Inc. ISRG31%+5.2 ppJun 2026
LeMaitre Vascular, Inc. LMAT27%+5.6 ppMar 2026
West Pharmaceutical Services, Inc. WST21%+5.7 ppJun 2026
Stevanato Group S.p.A. STVN14%+0.7 ppMar 2026
Align Technology, Inc. ALGN14%+0.2 ppJun 2026
Merit Medical Systems, Inc. MMSI12%+0.1 ppJun 2026
AptarGroup, Inc. ATR11%−1.9 ppJun 2026
Alcon Inc. ALC11%−8.1 ppMar 2026
Envista Holdings Corporation NVST8.9%+2.1 ppJun 2026
STAAR Surgical Company STAA8.5%+76.1 ppJun 2026
Repligen Corporation RGEN8.2%+4.3 ppJun 2026
Avantor, Inc. AVTR6.3%−3.0 ppJun 2026
Medline Inc. MDLN5.7%−2.9 ppMar 2026
Solventum Corporation SOLV4.0%−3.3 ppMar 2026
Teleflex Incorporated TFX3.7%−14.6 ppMar 2026
Bausch + Lomb Corporation BLCO2.7%+10.0 ppJun 2026
ICU Medical, Inc. ICUI2.6%+0.5 ppMar 2026
Baxter International Inc. BAX2.4%+0.2 ppJun 2026
Becton, Dickinson and Company BDX2.0%−6.5 ppMar 2026
Warby Parker Inc. WRBY0.7%−0.4 ppMar 2026
AtriCure, Inc. ATRC0.4%+5.2 ppJun 2026
BioLife Solutions, Inc. BLFS0.1%+2.4 ppMar 2026
The Cooper Companies, Inc. COO-2.9%−21.3 ppJun 2026
DENTSPLY SIRONA Inc. XRAY-4.0%−11.2 ppMar 2026
MiniMed Group, Inc. MMED-11%+9.3 ppJun 2026
Alamar Biosciences, Inc. ALMR-47%+17.9 ppMar 2026
Azenta, Inc. AZTA-115%−101.8 ppMar 2026
Kestra Medical Technologies, Ltd. KMTS-142%−5.1 ppJun 2026
Pulse Biosciences, Inc. PLSE—+98,992.5 ppMar 2026
Full 20-quarter history · every available company

OPM · reported quarter history

Showing the 12 largest of 29 companies with a series here. The remaining 17 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alcon Inc. · ALC

1.0%
8.5%
11%
9.0%
9.6%
1.0%
11%
11%
13%
8.8%
15%
13%
14%
16%
19%
9.5%
13%
12%
11%
—

Align Technology, Inc. · ALGN

26%
21%
20%
19%
16%
13%
14%
17%
17%
18%
16%
14%
17%
15%
13%
16%
9.7%
15%
14%
—

AptarGroup, Inc. · ATR

10%
11%
12%
12%
11%
11%
9.8%
13%
13%
10%
12%
14%
15%
14%
13%
15%
14%
11%
11%
—

Avantor, Inc. · AVTR

13%
11%
16%
16%
15%
14%
13%
4.1%
12%
11%
8.7%
10%
7.3%
11%
9.3%
7.7%
-40%
7.9%
6.3%
—

Baxter International Inc. · BAX

16%
11%
4.4%
7.3%
-80%
7.7%
3.7%
-0.5%
6.9%
11%
4.6%
6.6%
5.7%
-16%
2.2%
6.8%
6.1%
-25%
2.4%
—

Becton, Dickinson and Company · BDX

7.8%
15%
12%
12%
10%
13%
13%
11%
6.9%
9.3%
15%
12%
11%
8.8%
8.5%
16%
12%
11%
2.0%
—

Intuitive Surgical, Inc. · ISRG

32%
29%
27%
26%
26%
23%
23%
26%
27%
23%
25%
28%
28%
30%
26%
31%
30%
30%
31%
—

Medline Inc. · MDLN

—
—
—
—
—
—
—
—
—
—
9.2%
8.3%
9.0%
7.3%
8.6%
9.3%
8.1%
5.5%
5.7%
—

ResMed Inc. · RMD

29%
28%
27%
28%
29%
27%
27%
25%
26%
24%
31%
31%
32%
33%
33%
34%
33%
35%
35%
—

Solventum Corporation · SOLV

—
—
22%
22%
21%
19%
18%
20%
24%
20%
19%
12%
13%
6.6%
7.3%
9.9%
81%
6.2%
4.0%
—

The Cooper Companies, Inc. · COO

13%
17%
17%
16%
17%
12%
17%
11%
16%
15%
16%
17%
19%
20%
19%
18%
17%
13%
21%
-2.9%

West Pharmaceutical Services, Inc. · WST

26%
25%
26%
30%
27%
18%
22%
24%
24%
22%
18%
18%
22%
21%
15%
20%
21%
20%
21%
—

Margin change · reported quarter history

Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alcon Inc. · ALC

—
—
—
−1.9 pp
+8.6 pp
−7.5 pp
+0.2 pp
+2.1 pp
+3.0 pp
+7.8 pp
+3.6 pp
+1.6 pp
+0.9 pp
+7.0 pp
+3.9 pp
−3.2 pp
−0.8 pp
−4.3 pp
−8.1 pp
—

Align Technology, Inc. · ALGN

—
—
—
−7.2 pp
−9.6 pp
−8.9 pp
−6.2 pp
−2.2 pp
+1.2 pp
+5.4 pp
+1.3 pp
−2.9 pp
−0.7 pp
−3.4 pp
−2.1 pp
+1.8 pp
−6.9 pp
+0.3 pp
+0.2 pp
—

AptarGroup, Inc. · ATR

—
—
—
+1.6 pp
+1.4 pp
0.0 pp
−1.8 pp
+1.0 pp
+2.0 pp
−0.7 pp
+2.4 pp
+0.8 pp
+1.8 pp
+4.2 pp
+0.6 pp
+1.1 pp
−1.0 pp
−3.2 pp
−1.9 pp
—

Avantor, Inc. · AVTR

—
—
—
+1.8 pp
+2.0 pp
+2.8 pp
−2.7 pp
−11.4 pp
−2.7 pp
−3.4 pp
−4.3 pp
+6.2 pp
−4.9 pp
+0.8 pp
+0.6 pp
−2.6 pp
−47.3 pp
−3.5 pp
−3.0 pp
—

Baxter International Inc. · BAX

—
—
—
−6.4 pp
−95.7 pp
−3.2 pp
−0.7 pp
−7.8 pp
+86.7 pp
+3.5 pp
+0.9 pp
+7.1 pp
−1.2 pp
−27.0 pp
−2.4 pp
+0.2 pp
+0.4 pp
−8.7 pp
+0.2 pp
—

Becton, Dickinson and Company · BDX

—
—
—
+0.9 pp
+2.5 pp
−1.9 pp
+1.1 pp
−0.3 pp
−3.4 pp
−3.5 pp
+1.5 pp
+0.8 pp
+4.5 pp
−0.5 pp
−6.0 pp
+3.9 pp
+0.4 pp
+1.7 pp
−6.5 pp
—

Intuitive Surgical, Inc. · ISRG

—
—
—
−8.8 pp
−5.9 pp
−6.5 pp
−4.5 pp
+0.3 pp
+1.1 pp
+0.8 pp
+1.9 pp
+1.8 pp
+1.6 pp
+7.1 pp
+0.9 pp
+2.3 pp
+2.0 pp
−0.2 pp
+5.2 pp
—

Medline Inc. · MDLN

—
—
—
—
—
—
—
—
—
—
—
—
—
—
−0.6 pp
+1.0 pp
−0.9 pp
−1.8 pp
−2.9 pp
—

ResMed Inc. · RMD

—
—
—
+0.3 pp
0.0 pp
−0.7 pp
−0.2 pp
−3.4 pp
−2.8 pp
−3.4 pp
+4.4 pp
+6.7 pp
+5.4 pp
+8.8 pp
+1.7 pp
+2.5 pp
+1.8 pp
+2.1 pp
+1.9 pp
—

Solventum Corporation · SOLV

—
—
—
—
—
—
−3.3 pp
−1.4 pp
+3.2 pp
+0.7 pp
+0.7 pp
−8.4 pp
−11.1 pp
−13.3 pp
−11.6 pp
−1.8 pp
+67.4 pp
−0.4 pp
−3.3 pp
—

The Cooper Companies, Inc. · COO

—
—
—
—
+3.5 pp
−4.7 pp
+0.8 pp
−5.0 pp
−0.4 pp
+2.4 pp
−1.0 pp
+6.2 pp
+2.9 pp
+4.9 pp
+2.5 pp
+1.2 pp
−2.6 pp
−6.3 pp
+1.9 pp
−21.3 pp

West Pharmaceutical Services, Inc. · WST

—
—
—
+0.4 pp
+1.4 pp
−6.9 pp
−4.6 pp
−5.4 pp
−3.4 pp
+3.7 pp
−4.0 pp
−6.2 pp
−2.1 pp
−0.7 pp
−2.4 pp
+2.1 pp
−0.8 pp
−1.8 pp
+5.7 pp
—
07 · compare level, then change

Profit Scale & Acceleration

ResMed Inc. has the highest Net profit among the 30 Medical Instruments & Supplies companies compared here, at $1,521 million. Solventum Corporation is next at $1,432 million. Solventum Corporation has the highest Profit growth at the 100% top of the scoring scale, so level and change sit with different companies.

What the numbers say: ResMed Inc. leads with $1,521 million of TTM profit, 6.2% above Solventum Corporation. Solventum Corporation shows ≥100% on the scoring scale (277.8% uncapped) growth from a $1,432 million profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.

LeaderResMed Inc. · $1,521 million
Gap6.2% versus #2 · Solventum Corporation
Persistence8/8 recent comparable periods
Coverage16/30 companies · 519 observations

Investor read: ResMed Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
1ResMed Inc. RMD$1.5B
2Solventum Corporation SOLV$1.4B
3Becton, Dickinson and Company BDX$1.4B
4Medline Inc. MDLN$1.1B
5Alcon Inc. ALC$819M
Profit growthfastest growers
1Solventum Corporation SOLV100%
2LeMaitre Vascular, Inc. LMAT40%
3ResMed Inc. RMD16%
4Stevanato Group S.p.A. STVN13%
5Becton, Dickinson and Company BDX4.8%
Net profit · company comparison
16/30 level · 9/30 change
All-company data · latest reported quarter
CompanyNet profitProfit growthReported
Intuitive Surgical, Inc. ISRG$826M17%Jun 2026
ResMed Inc. RMD$399M9.3%Mar 2026
Medline Inc. MDLN$239M-26%Mar 2026
Alcon Inc. ALC$189M-46%Mar 2026
West Pharmaceutical Services, Inc. WST$139M54%Jun 2026
Align Technology, Inc. ALGN$113M22%Jun 2026
AptarGroup, Inc. ATR$73M-7.6%Jun 2026
Avantor, Inc. AVTR$43M-34%Jun 2026
Merit Medical Systems, Inc. MMSI$41M37%Jun 2026
Envista Holdings Corporation NVST$39M50%Jun 2026
ICU Medical, Inc. ICUI$31M-571%Mar 2026
Stevanato Group S.p.A. STVN$28M3.7%Mar 2026
LeMaitre Vascular, Inc. LMAT$16M45%Mar 2026
Solventum Corporation SOLV$13M-91%Mar 2026
Repligen Corporation RGEN$8M33%Jun 2026
STAAR Surgical Company STAA$5M-10%Jun 2026
Warby Parker Inc. WRBY$3M0.0%Mar 2026
BioLife Solutions, Inc. BLFS$1M-275%Mar 2026
AtriCure, Inc. ATRC$0M-112%Jun 2026
Teleflex Incorporated TFX$-5M-110%Mar 2026
DENTSPLY SIRONA Inc. XRAY$-10M-153%Mar 2026
Baxter International Inc. BAX$-17M-127%Jun 2026
Pulse Biosciences, Inc. PLSE$-18M—Mar 2026
Alamar Biosciences, Inc. ALMR$-21M—Mar 2026
Kestra Medical Technologies, Ltd. KMTS$-34M—Jun 2026
Becton, Dickinson and Company BDX$-37M-123%Mar 2026
Bausch + Lomb Corporation BLCO$-70M-400%Jun 2026
The Cooper Companies, Inc. COO$-78M-189%Jun 2026
Azenta, Inc. AZTA$-157M-133%Mar 2026
MiniMed Group, Inc. MMED$-185M—Jun 2026
Full 20-quarter history · every available company

Net profit · reported quarter history

Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alcon Inc. · ALC

$2M
$139M
$168M
$148M
$116M
$-97M
$174M
$169M
$204M
$427M
$248M
$223M
$263M
$284M
$350M
$176M
$237M
$217M
$189M
—

Align Technology, Inc. · ALGN

$181M
$191M
$134M
$113M
$73M
$42M
$88M
$112M
$121M
$124M
$105M
$97M
$116M
$104M
$93M
$125M
$57M
$136M
$113M
—

AptarGroup, Inc. · ATR

$47M
$58M
$62M
$64M
$54M
$59M
$55M
$83M
$84M
$62M
$83M
$90M
$100M
$101M
$79M
$112M
$128M
$74M
$73M
—

Avantor, Inc. · AVTR

$157M
$94M
$190M
$187M
$167M
$142M
$122M
$-7M
$108M
$99M
$60M
$93M
$58M
$500M
$65M
$65M
$-712M
$52M
$43M
—

Baxter International Inc. · BAX

$452M
$242M
$73M
$185M
$-3.0B
$144M
$0M
$-193M
$37M
$219M
$6M
$95M
$61M
$-488M
$64M
$122M
$-51M
$-1.0B
$-17M
—

Becton, Dickinson and Company · BDX

$155M
$568M
$390M
$390M
$288M
$509M
$460M
$407M
$108M
$281M
$537M
$487M
$400M
$303M
$158M
$574M
$493M
$382M
$-37M
—

Intuitive Surgical, Inc. · ISRG

$387M
$383M
$369M
$314M
$325M
$337M
$361M
$426M
$420M
$611M
$547M
$532M
$571M
$688M
$704M
$664M
$709M
$800M
$826M
—

Medline Inc. · MDLN

—
—
—
—
—
—
—
—
—
—
$295M
$292M
$324M
$289M
$322M
$333M
$322M
$180M
$239M
—

ResMed Inc. · RMD

$204M
$202M
$179M
$195M
$210M
$225M
$233M
$230M
$219M
$209M
$300M
$292M
$311M
$345M
$365M
$380M
$349M
$393M
$399M
—

Solventum Corporation · SOLV

—
—
$351M
$351M
$335M
$307M
$293M
$321M
$460M
$272M
$237M
$89M
$122M
$31M
$137M
$90M
$1.3B
$63M
$13M
—

The Cooper Companies, Inc. · COO

$616M
$110M
$95M
$127M
$98M
$66M
$85M
$40M
$85M
$85M
$81M
$89M
$105M
$118M
$104M
$88M
$98M
$85M
$131M
$-78M

West Pharmaceutical Services, Inc. · WST

$176M
$148M
$174M
$189M
$121M
$103M
$140M
$155M
$161M
$137M
$115M
$111M
$136M
$130M
$90M
$132M
$140M
$132M
$139M
—

Profit growth · reported quarter history

Showing the 12 largest of 26 companies with a series here. The remaining 14 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alcon Inc. · ALC

—
—
—
-2.0%
5,700%
-170%
3.6%
14%
76%
—
43%
32%
29%
-33%
41%
-21%
-9.9%
-24%
-46%
—

Align Technology, Inc. · ALGN

—
—
—
-44%
-60%
-78%
-34%
-0.9%
66%
195%
19%
-13%
-4.1%
-16%
-11%
29%
-51%
31%
22%
—

AptarGroup, Inc. · ATR

—
—
—
16%
15%
1.7%
-11%
30%
56%
5.1%
51%
8.4%
19%
63%
-4.8%
24%
28%
-27%
-7.6%
—

Avantor, Inc. · AVTR

—
—
—
18%
6.4%
51%
-36%
-104%
-35%
-30%
-51%
—
-46%
405%
8.3%
-30%
-1,328%
-90%
-34%
—

Baxter International Inc. · BAX

—
—
—
-39%
-762%
-41%
-100%
-204%
—
52%
—
—
65%
-323%
967%
28%
-184%
—
-127%
—

Becton, Dickinson and Company · BDX

—
—
—
-4.2%
86%
-10%
18%
4.4%
-63%
-45%
17%
20%
270%
7.8%
-71%
18%
23%
26%
-123%
—

Intuitive Surgical, Inc. · ISRG

—
—
—
-40%
-16%
-12%
-2.2%
36%
29%
81%
52%
25%
36%
13%
29%
25%
24%
16%
17%
—

Medline Inc. · MDLN

—
—
—
—
—
—
—
—
—
—
—
—
—
—
9.2%
14%
-0.6%
-38%
-26%
—

ResMed Inc. · RMD

—
—
—
0.0%
2.9%
11%
30%
18%
4.3%
-7.1%
29%
27%
42%
65%
22%
30%
12%
14%
9.3%
—

Solventum Corporation · SOLV

—
—
—
—
—
—
-17%
-8.6%
37%
-11%
-19%
-72%
-73%
-89%
-42%
1.1%
938%
103%
-91%
—

The Cooper Companies, Inc. · COO

—
—
—
—
-84%
-40%
-11%
-69%
-13%
29%
-4.7%
123%
24%
39%
28%
-1.1%
-6.7%
-28%
26%
-189%

West Pharmaceutical Services, Inc. · WST

—
—
—
1.1%
-31%
-30%
-20%
-18%
33%
33%
-18%
-28%
-16%
-5.1%
-22%
19%
2.9%
1.5%
54%
—
08 · compare level, then change

Return On Capital Employed

ResMed Inc. has the highest ROCE among the 30 Medical Instruments & Supplies companies compared here, at 7.1%. West Pharmaceutical Services, Inc. is next at 5.3%. Kestra Medical Technologies, Ltd. has the highest ROCE change at +21.7 percentage points, so level and change sit with different companies. 30 of 30 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: ResMed Inc. leads ROCE at 7.1%, 1.8 percentage points above West Pharmaceutical Services, Inc.. Kestra Medical Technologies, Ltd. has the strongest latest improvement at +21.7 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.

LeaderResMed Inc. · 7.1%
Gap34% versus #2 · West Pharmaceutical Services, Inc.
Persistence8/8 recent comparable periods
Coverage30/30 companies · 529 observations

Investor read: ResMed Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
1ResMed Inc. RMD7.1%
2West Pharmaceutical Services, Inc. WST5.3%
3Intuitive Surgical, Inc. ISRG5.2%
4Align Technology, Inc. ALGN3.5%
5AptarGroup, Inc. ATR3.4%
ROCE changefastest improvers
1Kestra Medical Technologies, Ltd. KMTS+21.7 pp
2STAAR Surgical Company STAA+9.3 pp
3AtriCure, Inc. ATRC+2.9 pp
4Pulse Biosciences, Inc. PLSE+1.9 pp
5MiniMed Group, Inc. MMED+1.7 pp
Return on capital · company comparison
30/30 level · 30/30 change
All-company data · latest reported quarter
CompanyROCEROCE changeReported
ResMed Inc. RMD7.1%+0.4 ppMar 2026
West Pharmaceutical Services, Inc. WST5.3%+0.3 ppJun 2026
Intuitive Surgical, Inc. ISRG5.2%+0.8 ppJun 2026
Align Technology, Inc. ALGN3.5%−0.4 ppJun 2026
AptarGroup, Inc. ATR3.4%−0.9 ppJun 2026
LeMaitre Vascular, Inc. LMAT3.2%+0.3 ppMar 2026
Merit Medical Systems, Inc. MMSI2.4%+0.3 ppJun 2026
Stevanato Group S.p.A. STVN2.0%+0.1 ppMar 2026
STAAR Surgical Company STAA2.0%+9.3 ppJun 2026
AtriCure, Inc. ATRC1.7%+2.9 ppJun 2026
Baxter International Inc. BAX1.3%+0.3 ppJun 2026
Medline Inc. MDLN1.2%−2.2 ppMar 2026
Avantor, Inc. AVTR1.2%0.0 ppJun 2026
Envista Holdings Corporation NVST1.2%+0.2 ppJun 2026
Solventum Corporation SOLV0.7%−0.5 ppMar 2026
Bausch + Lomb Corporation BLCO0.7%+0.8 ppJun 2026
Repligen Corporation RGEN0.5%0.0 ppJun 2026
ICU Medical, Inc. ICUI0.4%+0.1 ppMar 2026
Teleflex Incorporated TFX0.3%−0.7 ppMar 2026
Warby Parker Inc. WRBY0.3%−0.2 ppMar 2026
Becton, Dickinson and Company BDX0.2%−0.6 ppMar 2026
Alcon Inc. ALC0.0%−1.7 ppMar 2026
BioLife Solutions, Inc. BLFS0.0%+0.1 ppMar 2026
The Cooper Companies, Inc. COO-0.3%−1.9 ppJun 2026
DENTSPLY SIRONA Inc. XRAY-0.8%−2.1 ppMar 2026
MiniMed Group, Inc. MMED-2.5%+1.7 ppJun 2026
Azenta, Inc. AZTA-9.6%−8.7 ppMar 2026
Kestra Medical Technologies, Ltd. KMTS-14%+21.7 ppJun 2026
Alamar Biosciences, Inc. ALMR-15%0.0 ppMar 2026
Pulse Biosciences, Inc. PLSE-19%+1.9 ppMar 2026
Full 20-quarter history · every available company

ROCE · reported quarter history

Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alcon Inc. · ALC

0.1%
0.7%
1.0%
0.8%
0.8%
0.1%
1.0%
1.0%
1.1%
0.8%
1.4%
1.2%
1.2%
1.4%
1.7%
0.9%
1.2%
1.1%
0.0%
—

Align Technology, Inc. · ALGN

7.3%
5.9%
5.1%
4.9%
3.6%
2.8%
3.3%
4.3%
4.0%
4.3%
3.8%
3.6%
3.8%
3.5%
3.2%
3.9%
2.2%
3.7%
3.3%
3.5%

AptarGroup, Inc. · ATR

2.6%
2.7%
2.9%
3.0%
3.0%
2.6%
2.5%
3.5%
3.9%
2.6%
3.4%
3.8%
4.1%
3.7%
3.5%
4.3%
3.8%
2.9%
2.9%
3.4%

Avantor, Inc. · AVTR

2.4%
2.0%
2.9%
2.7%
2.5%
2.1%
1.9%
0.6%
1.8%
1.6%
1.3%
1.5%
1.1%
1.8%
1.4%
1.2%
-6.1%
1.3%
1.0%
1.2%

Baxter International Inc. · BAX

3.1%
1.7%
0.7%
1.2%
-14%
1.1%
0.5%
-0.1%
0.7%
1.3%
0.5%
0.8%
0.7%
-2.1%
0.3%
1.0%
0.9%
-4.0%
0.4%
1.3%

Becton, Dickinson and Company · BDX

0.8%
1.5%
1.2%
1.2%
1.1%
1.3%
1.3%
1.2%
0.8%
1.0%
1.6%
1.3%
1.3%
1.0%
0.8%
1.8%
1.5%
1.2%
0.2%
—

Intuitive Surgical, Inc. · ISRG

4.1%
4.0%
3.5%
3.3%
3.3%
3.1%
3.2%
3.7%
3.7%
3.6%
3.6%
4.1%
4.0%
4.8%
3.6%
4.4%
4.5%
4.9%
4.8%
5.2%

Medline Inc. · MDLN

—
—
—
—
—
—
—
—
0.0%
0.0%
—
—
1.7%
1.5%
3.4%
3.8%
1.7%
1.2%
1.2%
—

ResMed Inc. · RMD

6.4%
6.1%
5.9%
6.2%
6.4%
5.6%
5.9%
5.3%
5.5%
4.6%
6.2%
6.4%
6.3%
6.7%
6.7%
6.9%
6.7%
7.3%
7.1%
—

Solventum Corporation · SOLV

0.0%
0.0%
—
—
3.4%
3.1%
6.0%
6.8%
4.1%
3.3%
3.0%
2.0%
2.3%
1.1%
1.2%
1.7%
15%
1.1%
0.7%
—

The Cooper Companies, Inc. · COO

—
1.8%
1.5%
1.5%
1.5%
1.1%
1.5%
0.9%
1.5%
1.3%
1.4%
1.5%
1.8%
1.8%
1.6%
1.6%
1.6%
1.2%
1.9%
-0.3%

West Pharmaceutical Services, Inc. · WST

7.7%
7.3%
7.6%
8.7%
6.8%
4.5%
5.3%
6.1%
5.8%
5.1%
4.0%
4.2%
5.1%
5.1%
3.5%
5.0%
5.1%
4.7%
5.4%
5.3%

ROCE change · reported quarter history

Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alcon Inc. · ALC

—
—
—
—
+0.7 pp
−0.6 pp
0.0 pp
+0.2 pp
+0.3 pp
+0.7 pp
+0.4 pp
+0.2 pp
+0.1 pp
+0.6 pp
+0.3 pp
−0.3 pp
0.0 pp
−0.3 pp
−1.7 pp
—

Align Technology, Inc. · ALGN

—
—
—
—
−3.7 pp
−3.1 pp
−1.8 pp
−0.6 pp
+0.4 pp
+1.5 pp
+0.5 pp
−0.7 pp
−0.2 pp
−0.8 pp
−0.6 pp
+0.3 pp
−1.6 pp
+0.2 pp
+0.1 pp
−0.4 pp

AptarGroup, Inc. · ATR

—
—
—
—
+0.4 pp
−0.1 pp
−0.4 pp
+0.5 pp
+0.9 pp
0.0 pp
+0.9 pp
+0.3 pp
+0.2 pp
+1.1 pp
+0.1 pp
+0.5 pp
−0.3 pp
−0.8 pp
−0.6 pp
−0.9 pp

Avantor, Inc. · AVTR

—
—
—
—
+0.1 pp
+0.1 pp
−1.0 pp
−2.1 pp
−0.7 pp
−0.5 pp
−0.6 pp
+0.9 pp
−0.7 pp
+0.2 pp
+0.1 pp
−0.3 pp
−7.2 pp
−0.5 pp
−0.4 pp
0.0 pp

Baxter International Inc. · BAX

—
—
—
—
−17.3 pp
−0.6 pp
−0.2 pp
−1.3 pp
+14.9 pp
+0.2 pp
0.0 pp
+0.9 pp
0.0 pp
−3.4 pp
−0.2 pp
+0.2 pp
+0.2 pp
−1.9 pp
+0.1 pp
+0.3 pp

Becton, Dickinson and Company · BDX

—
—
—
—
+0.3 pp
−0.2 pp
+0.1 pp
0.0 pp
−0.3 pp
−0.3 pp
+0.3 pp
+0.1 pp
+0.5 pp
0.0 pp
−0.8 pp
+0.5 pp
+0.2 pp
+0.2 pp
−0.6 pp
—

Intuitive Surgical, Inc. · ISRG

—
—
—
—
−0.8 pp
−0.9 pp
−0.3 pp
+0.4 pp
+0.4 pp
+0.5 pp
+0.4 pp
+0.4 pp
+0.3 pp
+1.2 pp
0.0 pp
+0.3 pp
+0.5 pp
+0.1 pp
+1.2 pp
+0.8 pp

Medline Inc. · MDLN

—
—
—
—
—
—
—
—
—
—
—
—
+1.7 pp
+1.5 pp
—
—
0.0 pp
−0.3 pp
−2.2 pp
—

ResMed Inc. · RMD

—
—
—
—
0.0 pp
−0.5 pp
0.0 pp
−0.9 pp
−0.9 pp
−1.0 pp
+0.3 pp
+1.1 pp
+0.8 pp
+2.1 pp
+0.5 pp
+0.5 pp
+0.4 pp
+0.6 pp
+0.4 pp
—

Solventum Corporation · SOLV

—
—
—
—
+3.4 pp
+3.1 pp
—
—
+0.7 pp
+0.2 pp
−3.0 pp
−4.8 pp
−1.8 pp
−2.2 pp
−1.8 pp
−0.3 pp
+12.5 pp
0.0 pp
−0.5 pp
—

The Cooper Companies, Inc. · COO

—
—
—
—
—
−0.7 pp
0.0 pp
−0.6 pp
0.0 pp
+0.2 pp
−0.1 pp
+0.6 pp
+0.3 pp
+0.5 pp
+0.2 pp
+0.1 pp
−0.2 pp
−0.6 pp
+0.3 pp
−1.9 pp

West Pharmaceutical Services, Inc. · WST

—
—
—
—
−0.9 pp
−2.8 pp
−2.3 pp
−2.6 pp
−1.0 pp
+0.6 pp
−1.3 pp
−1.9 pp
−0.7 pp
0.0 pp
−0.5 pp
+0.8 pp
0.0 pp
−0.4 pp
+1.9 pp
+0.3 pp
09 · compare level, then change

Valuation Against Growth & Quality

LeMaitre Vascular, Inc. has the lowest PEG among the 30 Medical Instruments & Supplies companies compared here, at 1.09×. ResMed Inc. is next at 1.32×. Azenta, Inc. has the lowest P/E at 2.08×, so level and change sit with different companies. 6 of 30 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: LeMaitre Vascular, Inc. has the lowest comparable PEG at 1.09×, 17.4% below ResMed Inc.. Only 6 of 30 companies have earnings and growth steady enough for the ratio to mean anything, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.

LeaderLeMaitre Vascular, Inc. · 1.09×
Gap17.4% versus #2 · ResMed Inc.
Persistence0/8 recent comparable periods
Coverage6/30 companies · 82 observations

Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.
PEGlowest PEG
1LeMaitre Vascular, Inc. LMAT1.1
2ResMed Inc. RMD1.3
3Becton, Dickinson and Company BDX2.4
4The Cooper Companies, Inc. COO2.6
5Stevanato Group S.p.A. STVN2.7
P/Elowest P/E
1Azenta, Inc. AZTA2.1
2Solventum Corporation SOLV8.0
3Avantor, Inc. AVTR13.6
4ResMed Inc. RMD21.6
5AptarGroup, Inc. ATR22.6
Valuation · company comparison
6/30 level · 26/30 change
All-company data · latest reported quarter
CompanyPEGP/EReported
STAAR Surgical Company STAA11.684.6Jun 2026
Repligen Corporation RGEN8.7186.9Jun 2026
Alcon Inc. ALC6.445.4Mar 2026
Align Technology, Inc. ALGN3.429.3Jun 2026
AptarGroup, Inc. ATR3.322.6Jun 2026
Stevanato Group S.p.A. STVN2.723.3Mar 2026
Intuitive Surgical, Inc. ISRG2.745.6Jun 2026
The Cooper Companies, Inc. COO2.653.3Jun 2026
Becton, Dickinson and Company BDX2.439.8Mar 2026
Merit Medical Systems, Inc. MMSI2.328.7Jun 2026
West Pharmaceutical Services, Inc. WST1.946.0Jun 2026
ResMed Inc. RMD1.321.7Mar 2026
LeMaitre Vascular, Inc. LMAT1.140.3Mar 2026
Medline Inc. MDLN—32.6Mar 2026
Solventum Corporation SOLV—8.0Mar 2026
Baxter International Inc. BAX—39.6Jun 2026
Avantor, Inc. AVTR—13.6Jun 2026
Teleflex Incorporated TFX—28.0Mar 2026
Bausch + Lomb Corporation BLCO—775.5Jun 2026
Envista Holdings Corporation NVST—63.0Jun 2026
ICU Medical, Inc. ICUI—69.8Mar 2026
Warby Parker Inc. WRBY—1,053.5Mar 2026
DENTSPLY SIRONA Inc. XRAY—22.6Mar 2026
AtriCure, Inc. ATRC—133.2Jun 2026
BioLife Solutions, Inc. BLFS—228.4Mar 2026
Azenta, Inc. AZTA—2.1Mar 2026
Full 20-quarter history · every available company

PEG · reported quarter history

Showing the 12 largest of 13 companies with a series here. The remaining 1 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alcon Inc. · ALC

—
—
—
—
—
—
—
—
—
—
—
—
—
—
6.4
—
—
—
—
—

Align Technology, Inc. · ALGN

—
—
—
—
—
—
—
—
—
1.8
1.1
0.9
1.8
—
—
—
—
—
3.4
—

AptarGroup, Inc. · ATR

—
—
—
—
—
—
6.2
3.2
1.6
1.6
0.9
1.1
1.8
0.9
1.5
1.2
0.8
3.3
3.3
—

Becton, Dickinson and Company · BDX

—
—
—
—
—
—
—
—
—
—
—
—
2.2
0.9
3.2
2.4
—
—
—
—

Intuitive Surgical, Inc. · ISRG

—
—
—
—
—
—
—
—
5.7
1.8
1.4
1.7
1.7
3.0
3.1
3.3
2.8
3.1
2.7
—

LeMaitre Vascular, Inc. · LMAT

—
—
—
—
—
—
—
5.0
1.7
1.0
—
1.0
1.0
1.1
1.4
1.7
1.4
1.1
1.1
—

Merit Medical Systems, Inc. · MMSI

—
—
—
—
—
—
—
1.0
—
1.9
2.5
1.5
2.7
1.9
3.0
—
—
—
2.3
—

Repligen Corporation · RGEN

—
—
—
—
—
—
8.7
—
—
—
—
—
—
—
—
—
—
—
—
—

ResMed Inc. · RMD

—
—
—
—
—
—
3.5
2.4
1.6
2.9
2.8
2.0
1.4
0.7
0.7
0.7
1.0
1.2
1.3
—

Stevanato Group S.p.A. · STVN

—
—
—
—
—
—
3.0
2.4
8.9
—
—
—
—
—
—
4.8
2.0
2.1
2.7
—

The Cooper Companies, Inc. · COO

—
—
—
—
—
—
—
—
—
—
—
3.0
1.8
1.7
1.1
1.9
2.6
—
—
—

West Pharmaceutical Services, Inc. · WST

—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
1.9
—

P/E · reported quarter history

Showing the 12 largest of 26 companies with a series here. The remaining 14 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alcon Inc. · ALC

120.1
114.6
85.3
76.0
50.6
100.8
103.7
114.0
85.6
39.9
39.5
40.1
42.8
41.4
42.2
41.1
35.5
39.8
45.4
—

Align Technology, Inc. · ALGN

71.6
67.8
49.0
30.3
32.0
45.8
82.5
86.9
64.7
47.2
54.0
41.0
43.4
37.1
28.9
31.9
24.3
27.6
28.8
29.3

AptarGroup, Inc. · ATR

33.7
33.9
35.7
30.1
26.8
30.6
34.1
30.8
29.7
29.1
30.9
29.6
32.2
28.4
27.1
26.9
21.4
20.7
21.6
22.6

Avantor, Inc. · AVTR

51.8
49.6
38.0
33.4
20.9
20.9
23.0
32.6
39.0
48.6
65.6
39.3
56.2
20.3
15.6
13.6
—
—
—
—

Baxter International Inc. · BAX

21.6
33.9
37.1
32.1
—
—
—
—
7.5
7.4
8.3
6.0
39.6
—
—
—
—
—
—
—

Becton, Dickinson and Company · BDX

35.0
42.4
40.9
42.5
37.9
48.0
46.4
47.9
52.3
57.8
54.5
48.1
41.1
38.1
44.3
31.4
32.2
31.7
39.8
—

Intuitive Surgical, Inc. · ISRG

71.4
77.1
67.0
51.1
49.5
72.7
69.8
85.7
68.8
67.1
72.0
76.4
79.0
81.3
72.6
75.8
59.2
72.0
55.9
45.6

Medline Inc. · MDLN

—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
32.6
—

ResMed Inc. · RMD

77.3
73.4
45.7
39.6
40.8
37.8
37.3
35.9
24.0
28.4
30.4
27.7
32.3
27.0
25.1
27.1
28.0
23.8
21.7
—

Solventum Corporation · SOLV

—
—
—
—
—
—
—
—
—
—
9.3
8.7
16.8
23.9
35.2
35.1
8.4
8.9
8.0
—

The Cooper Companies, Inc. · COO

—
7.1
21.1
19.0
37.8
35.2
46.1
65.5
70.4
52.7
63.9
52.4
52.1
53.4
46.9
39.7
34.8
37.4
40.3
53.3

West Pharmaceutical Services, Inc. · WST

52.7
54.1
45.6
33.6
29.7
30.5
47.6
55.8
50.6
44.7
52.2
46.9
44.5
49.0
35.2
32.8
38.9
40.5
33.5
46.0
10 · before the conclusion, check the blind spots

What can make this comparison misleading?

This Medical Instruments & Supplies comparison names 4 specific ways its own evidence can mislead, all listed below. All 30 companies here report on comparable dates, so no rank carries a stale marker. A high growth rate can still be a low-base artefact.

Keep these limits visible

  • A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
  • A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
  • The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
  • An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
11 · evidence and freshness

How was this comparison built?

This comparison is built from the reported filings of 30 Medical Instruments & Supplies companies, normalized to a common $ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-08-04. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.

FundamentalsThrough Jun 2026 · up to 20 quarters per company
Market dataThrough 2026-08-04 · weekly price and relative-strength history
Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
12 · questions investors ask, short speakable answers

Medical Instruments & Supplies company comparison FAQs

These 22 answers restate the Medical Instruments & Supplies comparison above in question form. Every one is computed from the same 30 companies and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-08-04. Nothing here is estimated, and none of it is a recommendation.

Is the Medical Instruments & Supplies sector outperforming S&P 500?

Medical Instruments & Supplies has outperformed S&P 500 by 2.3% over 52 weeks and 18.1% over 13 weeks. 13 of 27 covered companies beat the S&P 500 on Mansfield relative strength, while 10 of 27 beat the sector itself.

Which Medical Instruments & Supplies company is largest by revenue?

Medline Inc. leads with revenue of $29,140 million, based on 14 of 30 comparable companies through Mar 2026.

Which Medical Instruments & Supplies company is growing fastest?

MiniMed Group, Inc. has the fastest current revenue growth at 14.3%, across 14 of 30 comparable companies.

Which Medical Instruments & Supplies company has the strongest 4-Factor Sector Score?

LeMaitre Vascular, Inc. ranks first at 61.8/100 with 81.1% evidence confidence. The score prioritizes research; it is not a buy recommendation.

Which Medical Instruments & Supplies company has the lowest comparable PEG?

LeMaitre Vascular, Inc. has the lowest comparable PEG at 1.09, among 6 of 30 companies whose earnings and growth are steady enough for the ratio to mean anything.

How much history does this Medical Instruments & Supplies comparison include?

The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.

How is the 4-Factor Sector Score calculated?

The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.

Which Medical Instruments & Supplies company is the biggest?

Medline Inc. is the largest, with trailing-twelve-month revenue of $29,140 million, ahead of Becton, Dickinson and Company at $21,366 million. That covers 14 of 30 companies with comparable reporting through Mar 2026.

Which Medical Instruments & Supplies company has the best profit margins?

ResMed Inc. has the highest operating margin at 34.9%, from 29 of 30 comparable companies. Pulse Biosciences, Inc. shows the biggest recent improvement, at +98992.5 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.

Which Medical Instruments & Supplies company makes the most profit?

ResMed Inc. earns the most, at $1,521 million of trailing-twelve-month net profit, from 16 of 30 comparable companies. Solventum Corporation has the fastest profit growth at 100%, though growth off a small or recovering profit base overstates how much has actually changed.

Which Medical Instruments & Supplies company earns the highest return on capital?

ResMed Inc. leads on return on capital employed at 7.1%, across 30 of 30 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.

Which Medical Instruments & Supplies stock is the cheapest?

On PEG — where a LOWER number is cheaper — LeMaitre Vascular, Inc. screens cheapest at 1.09×. Only 6 of 30 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.

Is the Medical Instruments & Supplies sector beating the market?

Medical Instruments & Supplies has outperformed S&P 500 by 2.3% over the last 52 weeks and 18.1% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 13 of 27 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.

Which Medical Instruments & Supplies stock has the strongest price momentum?

Pulse Biosciences, Inc. has the strongest relative strength against S&P 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.

Which Medical Instruments & Supplies company scores highest for research priority?

LeMaitre Vascular, Inc. scores 61.8 out of 100 with 81.1% evidence confidence, from 26.4 points on growth and earnings, 16.2 on capital efficiency, 13.8 on valuation and 5.4 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.

How many Medical Instruments & Supplies companies does this comparison cover, and over what period?

It compares 30 listed companies over up to 20 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.

What is the total market cap of the Medical Instruments & Supplies sector?

The 30 Medical Instruments & Supplies companies on this page carry $464,611 million of combined market value. Intuitive Surgical, Inc. is the largest at $130,100 million, about 28% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-04.

What is the Medical Instruments & Supplies sector's P/E ratio?

The median price-to-earnings ratio across the 30 Medical Instruments & Supplies companies on this page is 40.3×, measured on the 26 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 2026-08-04.

How is the Medical Instruments & Supplies sector performing?

13 of the 27 covered Medical Instruments & Supplies companies are beating S&P 500 on Mansfield relative strength. The sector itself is 2.3% ahead of S&P 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-04.

How many Medical Instruments & Supplies stocks are listed in the US?

This comparison covers 30 listed Medical Instruments & Supplies companies in the US, each above the size floor the site applies. The full ranked list is on this page, with reported fundamentals through Jun 2026. Membership is the full industry list — nothing is dropped for having thin data.

Why are some values on this page blank?

A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.

Is this investment advice?

No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI